Best Oncology Companies in Japan
The 75 best Oncology companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Chordia Therapeutics.
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Japan
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Chordia Therapeutics Developers of therapeutics for the treatment of cancer | $69M | 49 mo ago | Public | Hiroshi Miyake Co-Founder & CEO | 11 | Apple iCloud MailMicrosoft 365Apache HTTP Server+6 | 12 patents Solid tumor therapies using imidazopyridine biomarkers and MALT1/CLK kinase inhibitors | — |
| 2 | Anaeropharma Hypoxic environment targeted bacterial therapies for cancer | $49M | 107 mo ago | Deadpooled | Tetsuya Mishima CEO & President | 6 | — | — | — |
| 3 | Stella Pharma Developer of drugs for cancer radiation therapy | $31M | 123 mo ago | Public | Asano Tomoyuki CEO | 49 | WordPressPleskMySQL+14 | 152 patents Boronated amino acid compounds and formulations for neutron capture cancer therapy | — |
| 4 | J-Pharma Japanese, clinical stage biopharma company developing therapeutics for Oncology and other targets | $31M | 58 mo ago | Public | — | 24 | WordPressMySQLPHP+16 | 825 patents Formulating advanced drug delivery systems for metabolic, liver and inflammatory therapies. | 1 launch |
| 5 | SymBio Pharma SymBio Pharmaceuticals engages in in-license, development, and commercialization of drugs for the therapeutic… | $24M | 183 mo ago | Public | — | 152 | Apache HTTP ServerCloudflareGoogle Hosted Libraries+6 | — | — |
| 6 | Prism Biolab Japanese, clinical stage biotech developing small molecule therapeutics for cancer and fibrotic diseases. | $23M | 28 mo ago | Public | Takehara Co-CEO | — | WordPressMySQLPHP+25 | 59 patents Design of novel heterocyclic and bicyclic scaffolds for pharmaceutical drug discovery | — |
| 7 | Noile-Immune Biotech Developer of next-gen CAR-T immunotherapy platform for solid tumors | $22M | 63 mo ago | Public | — | 28 | Apache HTTP ServerAmazon Web ServicesUmami+7 | 134 patents Engineered CAR immune cells targeting mesothelin with IL-7/CCL19 for solid tumor therapy | — |
| 8 | Thyas Developer of induced pluripotent stem cells technology to treat cancer | $18M | 52 mo ago | Series B | — | 4 | — | 39 patents Engineered T‑cell generation from iPS cells for adoptive immunotherapy | — |
| 9 | SONIRE Therapeutics Developer of high intensity focused ultrasound treatment systems | $17M | 2 mo ago | Series B | Tohru Satoh Founder & CEO & President | 17 | WordPressMySQLPHP+12 | 59 patents High‑intensity focused ultrasound (HIFU) therapy devices and integrated ultrasound imaging systems | — |
| 10 | Gaia Biomedicine Provider of regenerative medicine for treating cancer | $13M | 11 mo ago | Series D | Yoshikazu Yoneman Founder | — | WordPressMySQLPHP+15 | 111 patents Engineered NK cell immunotherapies and membrane-anchored cytokine delivery platforms | — |
| 11 | B dot Medical Developer of proton beam therapeutic devices for the treatment of cancer | $13M | 8 mo ago | Series B | Takuji Furukawa President & CEO | 58 | — | 65 patents Advanced charged particle therapy delivery and patient transport systems | 1 award |
| 12 | Craif Developer of a device for cancer detection | $11M | 13 mo ago | Series C | Takao Yasui Co-Founder | 12 | microCMSApple iCloud MailGoogle Workspace+15 | 48 patents Microfluidic bioseparation and molecular diagnostics for biomarkers and genetic disease testing | — |
| 13 | FIMECS Developer of drugs targeting protein degradation in cancers | $10M | 52 mo ago | Series B | — | 34 | WordPressMySQLPHP+9 | 20 patents Design and synthesis of heterocyclic pharmaceutical intermediates for drug development | — |
| 14 | Celaid Therapeutics Developer of cell therapies for the treatment of blood cancer | $10M | 8 mo ago | Series B | Masatoshi Sakurai Co-Founder | 8 | — | 7 patents Cell cryopreservation media and stem cell culture formulations for therapeutic applications | — |
| 15 | Momotaro-Gene Provider of gene therapy to treat cancer | $10M | 38 mo ago | Series A | — | 7 | — | 92 patents Gene therapy delivering REIC/Dkk-3 for cancer immunotherapy and EGFR‑mutant lung cancer | — |
| 16 | Tella Dendritic cell vaccine for WT1 peptide | $9M | 107 mo ago | Deadpooled | — | 30 | WordPressMySQLPHP+15 | 34 patents Cancer immunotherapy via engineered T/NK cells and tumor antigen peptide therapeutics | — |
| 17 | Optieum Biotechnologies Developer of chimeric antigen receptor T-cell therapies for cancer | $8M | 17 mo ago | Series A | Toshiki Ochi Co-Founder | 4 | — | 2 patents Engineered CAR-T cells and therapeutic antibodies for cancer immunotherapy targeting specific antigens | — |
| 18 | PURMX Therapeutics Developer of gene therapies for cancer treatment | $8M | 25 mo ago | Series A | Hidetoshi Tahara CEO | — | WixSentryBootstrap+10 | 17 patents miRNA-based therapeutic compositions for cancer treatment | — |
| 19 | Alpha Fusion Developer of radiopharmaceuticals for cancer treatment | $7M | 20 mo ago | Series B | Nao Fujioka CEO | — | Radix UITailwind CSSshadcn/ui+10 | — | — |
| 20 | Repertoire TCR/BCR repertoire analysis services | $6M | 118 mo ago | Acquired | Ryuji Suzuki CEO & President | 20 | — | — | — |
| 21 | Red Arrow Therapeutics Provider of nanomedicine technology development services | $5M | 26 mo ago | Seed | — | 9 | — | — | — |
| 22 | Miltel Provider of telomere test for detection of aging | $5M | 30 mo ago | Series A | Eitoshi Tahara Founder | 27 | WordPressMySQLPHP+12 | — | — |
| 23 | KORTUC Developer of radiosensitizer for cancer therapy | $5M | 11 mo ago | Series B | Kazuyuki Matsuda CEO | 5 | WordPressMySQLPHP+12 | 104 patents Stable hydrogen peroxide prefilled syringes for medical/oncology applications | — |
| 24 | LinqMed Developer of radiopharmaceuticals for cancer treatment | $5M | 13 mo ago | Series B | Yukie Yoshii CEO | — | — | — | — |
| 25 | Lily MedTech A diagnostic imaging equipment for breast cancer detection | $3M | 98 mo ago | Series A | Shiho Azuma CEO | 17 | WordPress Block EditorWordPressMySQL+20 | 39 patents Ultrasonic medical imaging systems and diagnostic image processing technologies. | — |
| 26 | Vasculead Developer of combination therapy and peptide vaccine for cancer | $3M | 100 mo ago | Seed | Yosuke Suzuki Founder & CEO | — | — | 9 patents Therapeutic peptides targeting the PSF1 protein for cancer/immune modulation | — |
| 27 | Reborna Biosciences Developer of RNA-based drugs to treat rare genetic diseases | $2M | 10 mo ago | Series A | Koji Fuji Representative Director | 6 | WordPressMySQLPHP+8 | 26 patents Small‑molecule SMN2 splicing modulators for treating spinal muscular atrophy | — |
| 28 | Socium Provider of AI-enabled platform for drug discovery and development | $2M | 59 mo ago | Series A | Manabu Takahashi Co-Founder & CEO | 10 | — | 11 patents Patents concentrated in health & consumer products | — |
| 29 | HISHOH Biopharma Developer of immunotherapy for allergies | $2M | 58 mo ago | Seed | Naoki Sakurai CEO | — | — | — | — |
| 30 | HuLa immune Developer of therapeutic agents for autoimmune diseases and cancer treatment | $2M | 75 mo ago | Seed | Yasuhiro Shindo CEO & President | 11 | — | — | — |
| 31 | PhotoQ3 Developer of therapeutic technology for cancer treatment | $2M | 53 mo ago | Seed | Takao Hamakubo CEO | 4 | — | 18 patents Photodynamic therapy agents and tumor‑targeting pharmaceuticals for cancer treatment | — |
| 32 | Immunorock Developer of immunotherapies for the treatment of cancer and infectious diseases | $1M | 6 mo ago | Seed | Toshiro Shirakawa CEO | — | — | — | — |
| 33 | TKG Therapeutics Developer of therapeutics for cancer patients | $1M | 28 mo ago | Seed | Masaaki Matsui CEO | — | — | — | — |
| 34 | MediGear International Developer of nano-devices therapy for the treatment of cancer | $882K | 90 mo ago | Seed | — | 1 | — | — | — |
| 35 | Liquid Mine Developer of monitoring test system for early detection of leukemia recurrence | $768K | 12 mo ago | Series A | Tomoka Kishimoto CEO | 4 | — | — | — |
| 36 | AiRato AI-powered radiation therapy platform for cancer treatment | $533K | 7 mo ago | Seed | Yuto Kimura Co-Founder & Co-CEO | — | WordPressMySQLPHP+26 | — | — |
| 37 | Daiichi Sankyo Developer of drugs to address diverse medical needs | $236K | 57 mo ago | Public | Sunao Manabe CEO | 32,791 | DNNApple iCloud MailMicrosoft 365+13 | 7,796 patents Oncology antibody‑drug conjugates and multispecific immunotherapies targeting tumor antigens | 1 partnership |
Top 12 Oncology companies in Japan
#1
Series B · Tokyo, Tokyo · founded 2020 · 17 employees$17Mraised▾
Developer of high intensity focused ultrasound treatment systems. The companys system uses cavitation bubbles to enhance treatment efficacy and visualize the treatment process using heating systems. It offers treatment of pancreatic cancer using clinical trial assessing methods. It involves treating disease with high-energy ultrasound waves on a targeted area to destroy the cancer cells.
- Apr 2026Series B$18M
- Nov 2022Series B$17M
- Jun 2021Series A$4.8M
#2
Series B · Edogawa City, Tokyo · founded 2017 · 58 employees$13.1Mraised▾
Developer of proton beam therapeutic devices for the treatment of cancer. The company is involved in the development of an ultra-small proton beam cancer treatment device that uses a beam of protons to deliver radiation directly to the tumor cell. It is a cancer-killing machine that can target a patient's tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.
- Oct 2025Series B$8.8M
- Jun 2022Series A$13.1M
#3
Series B · Bunkyo, Tokyo · founded 2020 · 8 employees$10.2Mraised▾
Developer of cell therapies for the treatment of blood cancer. The company is developing hematopoietic stem cell therapy by using amplification technology for the treatment of blood cancers such as leukemia, malignant lymphoma, multiple myeloma, and intractable blood diseases such as aplastic anemia.
- Oct 2025Series B$7.2M
- May 2024Series A$3M
#4
Series D · Fukuoka, Fukuoka · founded 2015$13.2Mraised▾
GAIA Biomed provides regenerative medicine for treating cancer. It develops a new group of cell products (products such as regenerative medicine) for the treatment of cancer.
- Jul 2025Series D$13.2M
#5
Series C · Tokyo, Tokyo · founded 2018 · 12 employees$11.3Mraised▾
Developer of a device for cancer detection. The company has developed a novel device that is used to collect and separate the microRNA secreted from cancer cells present in the urine. The device uses a combination of zinc oxide nanostructures and microflow channel technologies for the process and early cancer detection.
- Apr 2025Series C$22M
- Dec 2024Series C$6.4M
- Mar 2024Series B—
- Apr 2022Series B—
#6
Seed · Kobe, Hyogo · founded 2021$1Mraised▾
Developer of immunotherapies for the treatment of cancer and infectious diseases. The company is focused on developing a cancer immunotherapy drug using an innovative oral vaccine platform technology which include B440 WT1 oral cancer vaccine and the BCOV332 oral Covid vaccine.
- Dec 2025Seed$315.4K
- Jul 2025Seed$1.2M
- Apr 2024Seed$292.5K
- Jul 2023Seed$747.8K
#7
Series B · Minato City, Tokyo · founded 2015 · 5 employees$5Mraised▾
Kortuc develops radiosensitizer for cancer therapy. The radiosensitize increases the effectiveness of radiotherapy for cancer. It refers to a cancer treatment method in which a mixture of hydrogen peroxide and hyaluronic acid is injected into tumors and a mixture of therapies.
- Jun 2025Series B$5M
- Jul 2021Seed—
- Dec 2019Seed—
#8
Series B · Chiba, Chiba · founded 2022$4.8Mraised▾
Developer of radiopharmaceuticals for cancer treatment. It offers a copper radioisotope 64Cu emitting a unique radioactive ray called Auger electron, which enables the treatment of cancer cells effectively with high energy.
- May 2025Series B$2.1M
- Apr 2025Series B$14M
- Jan 2025Series B$9.5M
- Dec 2023Series A—
#9
Series A · Kanagawa, kanto · founded 2018 · 6 employees$2.3Mraised▾
Developer of RNA-based drugs to treat rare genetic diseases. The company uses a proprietary drug discovery platform that enables the creation of therapeutic drugs that target RNA to treat rare genetic diseases including neuromuscular and cancer.
- Jul 2025Series A$5.3M
- May 2023Series A$4.8M
- Jun 2018Seed$2.3M
#10
Series A · Ehime · founded 2020 · 4 employees$8.4Mraised▾
Developer of chimeric antigen receptor T-cell therapies for cancer. The company has developed Eumbody System technology that enables to develop and detect scFv-based product candidates for therapeutic purposes. This technology has the potential to develop T-cell therapies for cancer, autoimmune and infectious diseases.
- Jan 2025Series A$8.4M
#11
Seed · Sendai, Miyagi · founded 2022$532.6Kraised▾
AI-powered radiation therapy platform for cancer treatment. The company focused on developing AIVOT, an AI-powered radiation therapy solution, automates various processes in intensity-modulated radiation therapy to cure as many cancers.
- Oct 2025Seed$1.1M
- Jun 2025Seed$3.1M
- Feb 2024Seed$532.6K
#12
Series B · Osaka, Osaka · founded 2021$6.9Mraised▾
Developer of radiopharmaceuticals for cancer treatment. It offers a lead compound Astatine-211 that emits alpha particles that selectively target and destroy the cancer cells in the human body.
- Oct 2024Series B$6.9M
- Mar 2023Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Japan
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,284 Japan-affiliated papers.
- Korea University81
- The University of Tokyo76
- Kyoto University64
- Okayama University63
- Kumamoto University53
- Tumor microenvironment9→155
- Cancer research15→119
- Immunotherapy5→96
- Cancer immunotherapy3→48
- Cytotoxic T cell2→33
- Tumor microenvironment24→315
- Immune system8→243
- Cancer research31→235
- Immunotherapy7→164
- Cancer immunotherapy3→72
- Immune system1→44
- Immunotherapy3→37
- Cancer research1→22
- Cancer immunotherapy2→15
- Immune checkpoint2→7
Where oncology is researched across Japan
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in Japan
Japan oncology patent filing is accelerating — 401 filings from 97 assignees (2016–2025), led by ONO Pharmaceutical, Daiichi Sankyo, Astellas Pharma; annual filings 3→42.
- ONO Pharmaceutical85
- Daiichi Sankyo39
- Astellas Pharma38
- NAT Cancer CT28
- Takeda Pharmaceuticals21
- UNIV Tohoku20
- SBI Pharmaceuticals19
- Momotaro GENE18
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.